ARCHIVES

JCO Retracts Key Duke Genomics Paper; Duke Shuts Down Three Phase II Trials

This article is from The Cancer Letter archive.

Vol. 36 No. 42 | November 19, 2010

Download PDF Visit The Full Archive

Related Articles

DCDDP Final Report; 3,557 Cancers, 90% By Mammography

July 9, 1982

Enck New ACCC President, King President Elect

March 20, 1987

Carlson Named NCCN Chief Executive

September 28, 2012

In Brief: Deisseroth Leaves M.D. Anderson To Head Yale’s Oncology, Gene Therapy Programs

September 15, 1995

FDA Advisors Oppose Group’s Tamoxifen Trial, But Okay The Idea

July 6, 1990

Phase II Elotuzumab Study Demonstrates 33 Months PFS

July 26, 2013